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Abstract
Background Human immunodeficiency virus (HIV) treat-
ment side effects have a deleterious impact on treatment
adherence,whichisnecessarytooptimizetreatmentoutcomes
including morbidity and mortality.
Purpose To examine the effect of the Balance Project
intervention, a five-session, individually delivered HIV treat-
ment side effects coping skills intervention on antiretroviral
medication adherence.
Methods HIV+ men and women (N=249) on antiretroviral
therapy (ART) with self-reported high levels of ART side
effect distress were randomized to intervention or treatment
as usual. The primary outcome was self-reported ART
adherence as measured by a combined 3-day and 30-day
adherence assessment.
Results Intent-to-treat analyses revealed a significant dif-
ference in rates of nonadherence between intervention and
control participants across the follow-up time points such
that those in the intervention condition were less likely to
report nonadherence. Secondary analyses revealed that
intervention participants were more likely to seek informa-
tion about side effects and social support in efforts to cope
with side effects.
Conclusions Interventions focusing on skills related to
ART side-effects management show promise for improving
ART adherence among persons experiencing high levels of
perceived ART side effects.
Keywords Side effects.Antiretroviral therapy.
Adherence.Compliance.RCT
Introduction
While the life-extending benefits of antiretroviral therapies
(ART) for human immunodeficiency virus (HIV) are well-
documented, aversive side effects accompany drug benefit [1].
Side effects are predictable, undesirable, and dose-related
pharmacologic effects that occur within therapeutic dose
ranges. The most common side effects from ART are gastro-
intestinal problems such as diarrhea, nausea and vomiting, and
dermatological problems such as rashes. Additional “unseen”
negative effects that become apparent over time include
cardiac and liver problems, bone loss, and increased triglyc-
eride levels [2]. Side effects are often cited when evaluating
the impact of ART on the HIV treatment arena [3–5]. While
newer ART drugs have fewer side effects, the goal of a
completely side effect-free, clinically effective regimen has
yet to be realized. As such, HIV-positive patients will have
to face the realities of side effects in the foreseeable future.
Perceived or anticipated side effects from ART have
been linked to failure in timely initiation and maintenance
of ART and are a threat to optimal adherence [6, 7]. Poor
ART adherence is related to virologic failure and resistance,
hastened disease progression, increased morbidity and
mortality, and elevated health care costs [1, 8–15]. Side
effects from ART are consistently found to predict poor
drug adherence [15, 16] and affect the acceptance and
maintenance of ART among those who may benefit from
treatment [17, 18]. In a sample of 2,765 persons with HIV
in four US cities, patients’ reports of several specific side
effects were associated with an increased likelihood of poor
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adherence seems to be one of which HIV+ individuals are
aware, with side effects consistently cited as a reason for
nonadherence to ART [20].
Side effects create a unique coping challenge. Unlike
disease-related symptoms, side effects may be coupled with
a belief that the problems are necessary to stay healthy (i.e.,
they are inevitably tied to the medication). Side effects may
also be viewed as ultimately controllable, that is, that one
has the power to stop taking medication and consequently
eliminate side effects [21–23]. Programs to help patients
manage ART side effects so that adverse effects do not
negatively impact adherence and treatment continuation offer
promise. The purpose of the current study was to evaluate the
impact of a one-on-one side effects coping intervention on
rates of nonadherence among adults living with HIV.
Methods
This study was conducted in San Francisco, CA, USA and
approved by the Institutional Review Board. Voluntary,
written informed consent was obtained from all participants.
The trial was registered at clinicaltrials.gov (NCT00643903).
Study Population
Between February 2005 and March 2007, HIV-infected
individuals were recruited from community agencies and
medical clinics to participate in a brief in-person interview
used to screen participants for eligibility in the randomized
intervention trial. To be considered for screening, potential
participants were required to be at least 18 years of age,
provide written informed consent, be taking a recognized ART
regimen (verified by documentation from pharmacy, letter
from provider, or examination of prescription bottles) for at
least the prior 30 days, and report not being currently involved
in another behavioral intervention study related to HIV. Severe
neuropsychological impairment and psychosis were assessed
on a case-by-case basis by interviewers in consultation with
senior project personnel, including the principal investigator, a
licensed clinical psychologist. Participants were eligible for
enrollment in the trial if they reported a level of side effect
distress on a previously used symptom/side-effect checklist
equivalent to the upper 40% of a prior sample [21, 22]. Those
who met criteria were scheduled for an enrollment visit and
baseline interview approximately 1 week later.
Design and Procedures
A double-baseline randomized controlled design of the
active intervention compared to treatment as usual was used
in this study. The double baseline was employed to observe
naturally occurring changes over time and regression to the
mean of key variables prior to randomization. Interviews
were conducted using laptop computers in private settings in
research offices. Procedures involved a combination of audio
computer-assisted self-interviewing (ACASI) and computer-
assisted personal interviewing (CAPI) using the Questionnaire
Development System (Nova Research Company, Bethesda,
MD, USA). ACASI has been shown to be an effective method
of decreasing social desirability bias and thereby enhancing
veracity of self-report of sensitive behaviors, including sexual
and substance use risk acts [24, 25]. The second baseline
interview was scheduled 3 months after the initial baseline
interview.
Randomization
Simple randomization was implemented immediately
following the second baseline interview using the SAS
System’s random number generator under the uniform
distribution, aligning treatments in order with consecutive
participant ID.
Intervention Condition
The Balance Project experimental intervention was
designed on the basis of prior studies of ART side effects
and adherence [19, 21, 22] and was based on elements of
social problem solving training [26, 27]a n dc o p i n g
effectiveness training [28] rooted in Stress and Coping
Theory [29]. It consisted of five 60-min individual
counseling sessions with each session designed around
topics relevant to ART side effects coping. See Table 1 for
an outline of the five sessions. Intervention sessions
followed a standard structure and set of activities, but were
individually tailored to participants’ specific life contexts,
stressors, and goals. Participants received $30 at the 3-month
assessment if they completed all five sessions prior to that
assessment interview. Participants in the control condition
receivedno activepsychosocialinterventions prior to the final
trial assessment interview.
Facilitators were master’s level clinicians with expertise
in HIV-related issues, were trained using standard materials,
and were “certified” if supervisors’ observations and
quality assurance ratings indicated skilled implementation.
All intervention sessions were audio recorded and 10%
were rated to ensure replication with fidelity.
Follow-up assessment interviews were scheduled at 3
(second baseline interview), 6, 9, and 15 months for both
the intervention and control groups. Participants received
$25 for completing the screening/enrollment interview, $40
for each of the two baseline assessment interviews and the
6-and 9-monthfollow-up interviews,and $50for the15-month
final interview.
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Basic demographic, treatment history, and health care
utilization data were collected by CAPI with trained
interviewers. Depression was assessed with the Beck
Depression Inventory II [30].
Medication Adherence
We assessed ART adherence using two well-validated self-
report measures. The first was the adherence measure
designed for the Adult AIDS Clinical Trials Group [31],
which assesses missed pills over the prior 3 days. This
measure has been used widely with diverse samples and the
short-term recall period has been associated with long-term
clinical outcomes. The measure was computerized for
ACASI administration to minimize the social desirability
associated with adherence reporting [31–33]. Mean 3-day
adherence was calculated by dividing the number of pills
reported as being taken by the number of pills that were
prescribed in the regimen. Second, we administered the
visual analog scale developed by Walsh [34] that assesses
Table 1 Outline of intervention sessions
Session Intervention topics
Session 1 Introductions and overview of intervention
Life history and HIV treatment history
General strengths and stressors
HIV treatment related stressors
Goal setting
Introduce positive affect amplification
Session 2 Review of prior session and progress toward goal
Introduction of stress and coping model
Coping effectiveness training
Breaking down stressors from general to specific
Distinguishing between changeable and unchangeable
Facilitated problem solving related to a medication stressor
Goal setting
Positive affect amplification exercise
Session 3 Review of prior session and progress toward goal
Emotion vs. problem focused coping in HIV treatment
Social support skills
Distinguish tangible, emotional and informational support
Identify positive vs. negative social support
Explore/Diagram current social support network
Problem solve social support building around side effect stressors
Goal setting
Positive affect amplification exercise
Session 4 Review of prior session and progress toward goal
Identifying strengths and challenges in provider relationships
Active listening and assertive communication with providers
Facilitated problem solving related to communication with providers
Goal setting
Positive affect amplification exercise
Session 5 Review of prior session and progress toward goal
Cognitive traps in coping and adherence (self-sabotaging thoughts)
Cognitive facilitators in coping and adherence (self-enhancing thoughts)
Barriers to adherence
Identify what has changed
Problem solve a remaining adherence barrier
Goal setting
Discuss how to maintain momentum
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a continuum anchored by “0%” to “100%.” This measure
has shown to be correlated with other measures of adherence,
such as medication event monitoring systems [35, 36]a n da
30-day timeframe has recently been supported as preferable
to other approaches of self-report [37]. For the visual analog
scale, the mean percent adherence was calculated across all
drugs in the participant’s regimen. Because there is a
tendency for people to over-report adherence on these
measures, we defined nonadherence as less than perfect
adherence on either the AIDS Clinical Trial Group Measure
or the visual analog scale, thus establishing a conservative
definition of self-reported nonadherence.
Coping with Side Effects
To monitor changes in ways of coping with treatment side
effects associated with the Balance Project intervention, we
administered the SECope at each assessment timepoint
[38]. This 20-item measure assesses strategies for coping
with HIV-treatment side effects, and includes scales of
Positive Emotion Focused Coping, Social Support Seeking,
Nonadherence, Information Seeking, and Taking Side
Effect Medications, all with evidence of reliability and
validity from prior studies [38].
Statistical Analysis
One-way and cross-tabular frequency tables were generated
for categorical variables; means and standard deviations
were generated as measures of central tendency for
continuous variables. Primary inferential analyses consisted
of random coefficient multilevel (i.e., HLM) models that
contained random intercepts or random intercepts and
slopes to model within-participant correlations of responses
over time, providing a unified method to model both binary
(i.e., nonadherence) and continuous outcomes (i.e., the
coping measures). Each model contained fixed main effect
terms for group assignment (intervention vs. control), time
of measurement (treated as a continuous variable with
measurement points of baseline, 3, 6, 9, and 15 months),
and their interaction. Random effects consisted of
participant-specific intercepts or participant-specific random
intercepts and slopes. Models involving the continuous
SECope outcomes also added a single level 1 residual
variance estimate, which is customary in random coefficient
modeling. Additional within-group slope coefficients and
confidence intervals were produced for models that exhibited
a statistically significant group-by-time interaction effect. For
each outcome, a model with random intercepts only was
comparedtoa model with randomintercepts, slopes, and their
covariance using the Bayesian Information Criterion [39].
Random effects models were fitted using SAS PROC
GLIMMIX version 9.2. Parameter estimation was obtained
through maximum likelihood estimation with integral
approximation via adaptive Gaussian quadrature with 15
integration points. To guard against possible misspecifica-
tionofthemodelcovariancestructuresinfluencinginferences,
variance estimation was performed using Morel’sr o b u s t
variance estimator [40]. Linearity of the continuous time
effect was assessed using the cumulative-sums-of-residuals
method [41]. Histograms and predicted value-by-residual
scatterplots were used to evaluate normality and homosce-
dasticity of the model residuals, respectively.
Results
Participant Characteristics
Table 2 provides details of the participant characteristics for
each randomization group. The sample was predominately
male, with 55% identifying as White, 18% as African
American or Black, and 15% as Hispanic. The mean age
was 46 years, the mean time since testing HIV positive was
almost 14 years, and the mean time since starting a first
ART regimen was 10 years. The most frequently endorsed
symptoms that were attributed to ARTand the proportion of
respondents reporting them were as follows: fatigue or loss
of energy (96.4%), feelings of sadness and depression
(82.3%), sleep problems (78.6%), muscle aches or joint
pain (75.5%), and stomach bloating, pain, or gas (74.7%).
The sample was balanced across randomization conditions
with regard to all demographic, treatment, side effect, and
depression variables.
Assessment and Intervention Completion Rates
Of the 249 individuals enrolled in the trial and randomized,
95% completed the 6-month assessment, 93% completed
the 9-month assessment, and 93% completed the final 15-
month assessment. Of the 128 individuals randomized to
the intervention condition, 116 (91%) completed the first
session and 112 (88%) completed all five sessions. See
Fig. 1 for the trial participant flow details. Attrition rates
across the two conditions were not different, suggesting that
the extra incentive payment for intervention completion did
not differentially affect study retention.
Model Diagnostics
Assessments of linearity via cumulative sums of residuals
supported the null hypothesis of linear time effects for all
outcomes (p>0.10 for all assessments). Examination of
residuals’ histograms and predicted-value-by-residual-value
86 ann. behav. med. (2011) 41:83–91scatterplots indicated approximate normality and constant
variance of model residuals. For all outcomes studied, the
Bayesian Information Criterion preferred the more parsi-
monious random intercepts model to the more complex
random intercepts-plus-slopes model. Consequently, all
results reported below originate from random intercept-only
models.
Nonadherence
A statistically significant group-by-time interaction effect
was obtained, such that control group and intervention
group participants differed in non-adherence change over
time (see Table 3 and Fig. 2). Specifically, within-group
slopes analysis revealed that the odds of non-adherence
544 Assessed for Eligibility
295 Excluded
   210 Not Meeting Inclusion Criteria
   85 Declined 
128 Assigned to Intervention 
         116 (91%) Received Intervention as Assigned
249 Randomized
121 Assigned to Wait List Control 
        
10 Lost to Follow-up
4 Discontinued Intervention 
         
8 Lost to Follow-up
         
128 Included in Analysis
0 Excluded From Analysis 
         
121 Included in Analysis
0 Excluded From Analysis 
         
Fig. 1 Trial flow diagram
Table 2 Sample characteristics
Control (N=121) Intervention (N=128) Total
a (N=249)
Age (years) (mean SD) 46.0 (7.5) 46.3 (8.3) 46.2 (7.9)
Gender n (%)
Male 110 (90.9) 116 (90.6) 226 (90.8)
Female 11 (9.1) 12 (9.4) 23 (9.2)
Race/ethnicity n (%)
Black 24 (19.8) 22 (17.2) 46 (18.5)
White 63 (52.1) 75 (58.6) 138 (55.4)
Latino/a 22 (18.2) 16 (12.5) 38 (15.3)
Other 12 (9.9) 15 (11.7) 27 (10.8)
Sexual orientation n (%)
Homosexual 91 (75.2) 101 (78.9) 192 (77.1)
Heterosexual 18 (14.9) 15 (11.7) 33 (13.3)
Bisexual/other 12 (9.9) 12 (9.4) 24 (9.6)
Graduated high school n (%) 111 (91.7) 119 (93.0) 230 (92.4)
Currently not working n (%) 91 (75.2) 83 (64.8) 174 (69.9)
BDI-II depression score 17.7 (9.8) 18.0 (9.8) 17.9 (9.8)
Number of ART meds at baseline 3.1 (1.0) 3.2 (.9) 3.1 (1.0)
Number of ART doses/day at baseline 4.3 (1.8) 4.5 (1.7) 4.4 (1.7)
Viral load undetectable n (%) 80 (66.7) 88 (68.8) 168 (67.7)
CD4 count (mean SD) 404.1 (221.4) 433.0 (274.7) 419.1 (250.4)
Years since tested HIV-positive (mean SD) 13.8 (6.3) 13.8 (5.8) 13.8 (6.1)
Years since first started ART (mean SD) 9.9 (5.8) 10.1 (5.7) 10.0 (5.7)
aAll p values comparing control to intervention were >0.05
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in the control group (OR=1.03; 95% CI=0.96, 1.10; p=
0.40) whereas the odds of non-adherence decreased 6% per
month for the average participant in the intervention group
(OR=0.94; 95% CI=0.89, 0.99; p=0.02).
Coping with Side Effects
No statistically significant group, time, or group-by-time
effects were observed for the SECope Positive Emotion
Focused Coping, Taking Side Effect Medications, or Non-
Adherence subscales (Table 3). A significant overall differ-
ence between control and intervention group participants was
found, however, such that control participants reported using
side-effects management strategies less than their intervention
group counterparts. Statistically significant group-by-time
interaction effects were obtained for the Social Support and
Information Seeking subscales, such that control group
participants reported using these strategies less often than
intervention participants did during the study (Table 4).
Within-groups slopes analyses showed no change in inter-
vention participants’ use of social support (B=0.001;
95% CI=−0.01, 0.01; p=0.83) and information seeking
(B=0.002; 95% CI=−0.01, 0.01; p=0.73). However,
control participants’ seeking of both social support (B=−0.02;
95% CI=−0.03, −0.01; p=0.001) and information (B=−0.02;
95% CI=−0.03, −0.01; p=0.007) decreased over time
(Tables 3 and 4).
Table 3 Non-adherence and coping with side effects measures: random effects regression results
Outcome Intercept Fixed effects Random effects
Group Time Group×time Random
Intercept
Residual
Non-Adh 3.48 (2.69, 4.27)*** −0.38 (−1.34, −0.58) −0.07 (−0.12,−0.01)* 0.10 (0.01, 0.18)* 4.60 (2.98, 8.02) –
SECope P 3.53 (3.42, 3.65)*** −0.03 (−0.20, 0.13) 0.003 (−0.01, 0.01) −0.01 (−0.02, 0.01) 0.30 (0.24, 0.37) 0.21 (0.19, 0.23)
SECope N 1.35 (1.26, 1.44)*** 0.04 (−0.09. 0.17) −0.003 (−0.01. 0.01) −0.004 (−0.01, 0.01) 0.16 (0.13, 0.21) 0.14 (0.13, 0.16)
SECope T 2.46 (2.28, 2.63)*** −0.30 (−0.56,−0.03) −0.01 (−0.02, 0.01) 0.01 (−0.01, 0.03) 0.56 (0.44, 0.72) 0.84 (0.77, 0.93)
SECope S 2.56 (2.42, 2.70)*** 0.08 (−0.13, 0.28) 0.001 (−0.01, 0.01) −0.02 (−0.03.−0.003)* 0.44 (0.37, 0.55) 0.29 (0.27, 0.32)
SECope I 2.91 (2.76, 3.06)*** 0.18 (−0.04, 0.39) 0.002 (−0.01, 0.01) −0.02 (−0.04,−0.002)* 0.50 (0.42, 0.64) 0.40 (0.37. 0.44)
N=249 for all analyses. Intercept represents the expected value of the intervention group. Group represents the difference between the control
group and intervention group. Time is measured in months (0.25, 3, 6, 9, and 15) and represents the intervention group’s change in the outcome
over time. Group×time represents the difference in slopes between the control and intervention groups. Non-Adh non-adherence. SECope P
positive emotion-focused coping, SECope N non-adherence strategies, SECope T taking side-effects medications, SECope S social support
seeking, SECope I information seeking
*p<0.05, **p<0.01; ***p<0.001
Note:  Intervention was delivered between months 3 and 6.  Overall group x time 
interaction was significant (p<.05) 
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The findings from the current trial support the five-session
Balance Project intervention to promote ART adherence
among HIV-positive adults experiencing high levels of
perceived ART side effects. Follow-up analyses suggest
that the intervention may have been particularly effective in
influencing individuals’ efforts to access information and
social support for coping with HIV treatment side effects.
This is the first published trial to demonstrate beneficial
effects on ART adherence by focusing on side-effects
management. Consistent with the evidence that side effects
are associated with nonadherence, these results demonstrate
that efforts to improve patients’ side-effects management
skills have the potential to reverse the negative impact of
perceived side effects on ART adherence.
The current intervention, although individually deliv-
ered, was relatively low dose compared to other behavioral
interventions in health care contexts, which sometimes
prescribe 15 or more sessions [42, 43]. A low-dose
intervention may be readily implemented in clinics and
agencies that provide health care and support to persons
living with HIV. There is also the potential for elements of the
intervention to be delivered prior to the initiation of ART.
Suchinterventionsmayoffsettheharmfuleffectofanticipated
side effects on future rates on ART uptake by giving side-
effects management skills to people prior to initiating therapy.
Preemptive intervention may be considered in the context of
building patients’ readiness for ARTand may result in greater
ART uptake and subsequent adherence and maintenance of
ART in the face of side effects that may develop. This
intervention approach may also be particularly useful if there
isa needtochangeARTregimensfollowingtreatment failure,
a context in which there may be a higher perception or actual
increased probability of significant side effects during the
initial period of a new regimen.
Although designed and implemented in the context of
HIV disease, the intervention is rooted in broader theories
of health promotion and behavior change, including Stress
a n dC o p i n gT h e o r y[ 29] and Social Problem Solving
Theory [26, 44]. Consequently this intervention approach
may be appropriate for other illness contexts in which side
effects from treatment represent a substantial barrier to
adherence and optimal outcomes.
There are several noteworthy limitations in the current
study. First, the experimental design used a treatment as
usual comparison rather than a matched attention control
condition, so it is impossible to determine the potential
confounding effects of increased attention by trial staff in
the experimental condition rather than the control condi-
tion. Further, the assessment did not capture comprehensive
data on access and use of adherence resources outside of
the trial, a construct that is gaining attention in adherence
research [45]. Second, the use of self-reported adherence
data, while supported by validity studies [46] has been
questioned in HIV research as being inflated because of
recall, social desirability, and other biases. To minimize the
biases inherent in self-reported data, we employed several
techniques. We used conservative cut-offs of validated
measures of adherence that have demonstrated meaningful
relationships with important outcomes, such as viral load,
in other studies. ACASI interviewing for the adherence
portion of the interview was used, thereby removing the
interviewer’s presence and minimizing social desirability
bias. Such approaches to computerized adherence assess-
ment have shown favorable effects in other studies [47].
Despite these strategies, it should be noted that the use of
self-reported adherence outcomes remains a limitation of
the study, and results may have differed if other adherence
assessment approaches had been used. Third, because the
study used a convenience sample rather than a probability-
based sample, there are limits of the degree to which
Table 4 Proportions of non-adherence and mean levels of SECope
Outcome Baseline (N=249) 3 Months (N=249) 6 Months (N=237) 9 Months (N=232) 15 Months (N=231)
C( N=121) I (N=128) C (N=119) I (N=123) C (N=112) I (N=114) C (N=104) I (N=107) C (N=101) I (N=102)
Non-adherence (N %) 103 (85.1) 112 (87.5) 105 (86.8) 116 (90.6) 107 (91.5) 106 (88.3) 103 (88.8) 96 (82.8) 99 (88.4) 96 (81.4)
Coping (mean SD)
Information seeking 3.18 (.92) 2.92 (.91) 2.99
a (.94) 2.82 (.92) 2.94 (.97) 3.00 (1.00) 2.97 (.99) 2.92 (.95) 2.91 (.98) 2.91 (.92)
Non-adherence 1.38 (.56) 1.40 (.55) 1.43
a (.60) 1.34 (.57) 1.37 (.59) 1.28 (.45) 1.31 (.52) 1.29 (.53) 1.35 (.50) 1.38 (.58)
Positive emotion
focus
3.51 (.74) 3.58 (.67) 3.47 (.66) 3.49 (.74) 3.51 (.70) 3.55 (.72) 3.52 (.65) 3.55 (.73) 3.46 (.74) 3.62 (.69)
Social support 2.64 (.88) 2.58 (.84) 2.62 (.82) 2.52 (.82) 2.53 (.92) 2.57 (.82) 2.48 (.82) 2.52 (.90) 2.44 (.90) 2.63 (.79)
Taking side-effect
meds
2.16 (1.23) 2.44 (1.20) 2.21 (1.11) 2.50
a (1.25) 2.17 (1.13) 2.34 (1.22) 2.20
a (1.10) 2.45 (1.16) 2.27 (1.19) 2.36 (1.22)
C Control group, I intervention group. Participants were randomized following the 3-month measurement occasion
aIndicates instances where one observation was missing due to participant non-response. N varies because SECope was not administered if participant
reported no side effects at follow up
ann. behav. med. (2011) 41:83–91 89findings are generalizable to other populations. Related, the
sample was predominately male, and thus caution should be
exercised when generalizing the findings to women.
Finally, because the eligibility criteria did not select based
on levels of adherence at baseline, there was a limit of the
degree to which patients could improve on their adherence,
as some reported perfect adherence at study entry. However,
evenwiththepotentialceilingeffectofadherencescoresinthe
sample, the intervention was shown to significantly protect
against the likelihood of subsequent nonadherence.
In summary, this study supported the hypothesis that
improving coping skills related to HIV treatment side effects
canhavea protectiveeffectontreatment adherence.While the
side-effect burden associated with available HIV treatments
has lessened over recent years with the development of new
drugs, a truly side effect-free ART regimen has not yet been
developed. Therefore, treatment side effects are likely to
remain a substantive threat to adherence. Interventions aimed
at mitigating the impact of side effects on treatment adherence
offer promise to help optimize treatment outcomes for the
growing numbers of people living with HIV.
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